CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-27..
- Stock-based compensation / revenue · 12 months: Value 2.08%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-27..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 2.08% | Share-based compensation / revenue. Period ending 2026-06-27. $83.06M ÷ $4.00B × 100 ≈ 2.08% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 4.00B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 83.06M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 90.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | (m) | $4.00B | $83.06M | $90.14M | (m) | (m) | 2.08% | (m) | (m) |
| 2026-03-28 | (m) | $4.03B | $80.33M | $70.39M | (m) | (m) | 1.99% | (m) | (m) |
| 2025-12-27 | (m) | $4.02B | $71.08M | $25.16M | (m) | (m) | 1.77% | (m) | (m) |
| 2025-09-27 | (m) | $4.02B | $70.69M | $140.91M | (m) | (m) | 1.76% | (m) | (m) |
| 2025-06-28 | (m) | $4.03B | $66.75M | $124.52M | (m) | (m) | 1.66% | (m) | (m) |
| 2025-03-29 | (m) | $4.02B | $66.29M | $176.04M | (m) | (m) | 1.65% | (m) | (m) |
| 2024-12-28 | (m) | $4.05B | $69.89M | $227.35M | (m) | (m) | 1.73% | (m) | (m) |
| 2024-09-28 | (m) | $4.06B | $72.18M | $527.96M | (m) | (m) | 1.78% | (m) | (m) |
| 2024-06-29 | (m) | $4.08B | $75.64M | $562.05M | (m) | (m) | 1.86% | (m) | (m) |
| 2024-03-30 | (m) | $4.11B | $75.33M | $575.35M | $137.33M | (m) | 1.83% | 4.19× | Reported |
| 2023-12-30 | (m) | $4.13B | $72.05M | $617.26M | $136.71M | (m) | 1.74% | 4.52× | Reported |
| 2023-09-30 | (m) | $4.22B | $74.60M | $648.15M | $137.94M | (m) | 1.77% | 4.70× | Reported |
| 2023-07-01 | (m) | $4.18B | $73.80M | $647.62M | $115.58M | (m) | 1.77% | 5.60× | Reported |
| 2023-04-01 | (m) | $4.09B | $72.46M | $670.09M | $84.24M | (m) | 1.77% | 7.95× | Reported |
| 2022-12-31 | (m) | $3.98B | $73.62M | $650.98M | $59.29M | (m) | 1.85% | 10.98× | Reported |
| 2022-09-24 | (m) | $3.78B | $70.73M | $659.97M | $36.06M | (m) | 1.87% | 18.30× | Reported |
| 2022-06-25 | (m) | $3.69B | $70.76M | $664.80M | $41.14M | (m) | 1.92% | 16.16× | Reported |
| 2022-03-26 | (m) | $3.63B | $72.90M | $614.94M | $53.63M | (m) | 2.01% | 11.47× | Reported |
| 2021-12-25 | (m) | $3.54B | $71.47M | $589.86M | $73.91M | (m) | 2.02% | 7.98× | Reported |
| 2021-09-25 | (m) | $3.43B | $67.66M | $545.98M | $95.51M | (m) | 1.97% | 5.72× | Reported |
| 2021-06-26 | (m) | $3.27B | $62.50M | $522.93M | $97.92M | (m) | 1.91% | 5.34× | Reported |
| 2021-03-27 | (m) | $3.04B | $58.57M | $462.15M | $101.08M | (m) | 1.93% | 4.57× | Reported |
| 2020-12-26 | (m) | $2.92B | $56.34M | $432.73M | $86.43M | (m) | 1.93% | 5.01× | Reported |
| 2020-09-26 | (m) | $2.82B | $54.81M | $412.59M | $77.65M | (m) | 1.94% | 5.31× | Reported |
| 2020-06-27 | (m) | $2.75B | $51.97M | $372.64M | $64.48M | (m) | 1.89% | 5.78× | Reported |
| 2020-03-28 | (m) | $2.72B | $55.33M | $375.64M | $65.96M | (m) | 2.03% | 5.69× | Reported |
| 2019-12-28 | (m) | $2.62B | $57.27M | $351.15M | $60.88M | (m) | 2.18% | 5.77× | Reported |
| 2019-09-28 | (m) | $2.53B | $54.87M | $344.84M | $53.26M | (m) | 2.17% | 6.47× | Reported |
| 2019-06-29 | (m) | $2.45B | $52.66M | $336.40M | $64.76M | (m) | 2.15% | 5.19× | Reported |
| 2019-03-30 | (m) | $2.38B | $49.70M | $333.35M | $62.57M | (m) | 2.09% | 5.33× | Reported |
| 2018-12-29 | (m) | $2.27B | $47.35M | $331.38M | $63.77M | (m) | 2.09% | 5.20× | Reported |
| 2018-09-29 | (m) | $2.14B | $47.01M | $290.94M | $54.76M | (m) | 2.19% | 5.31× | Reported |
| 2018-06-30 | (m) | $2.02B | $46.72M | $280.64M | $45.23M | (m) | 2.31% | 6.21× | Reported |
| 2018-03-31 | (m) | $1.91B | $45.06M | $285.62M | $33.98M | (m) | 2.36% | 8.40× | Reported |
| 2017-12-30 | (m) | $1.86B | $44.00M | $287.50M | $29.78M | (m) | 2.37% | 9.66× | Reported |
| 2017-09-30 | (m) | $1.85B | $43.90M | $293.86M | $29.56M | (m) | 2.38% | 9.94× | Reported |
| 2017-07-01 | (m) | $1.81B | $42.97M | $278.67M | $28.98M | (m) | 2.38% | 9.62× | Reported |
| 2017-04-01 | (m) | $1.77B | $43.19M | $255.42M | $30.48M | (m) | 2.44% | 8.38× | Reported |
| 2016-12-31 | (m) | $1.68B | $43.64M | $237.42M | $27.71M | (m) | 2.60% | 8.57× | Reported |
| 2016-09-24 | (m) | $1.57B | $42.42M | $220.60M | $24.02M | (m) | 2.70% | 9.18× | Reported |
| 2016-06-25 | (m) | $1.49B | $42.30M | $217.24M | $20.79M | (m) | 2.83% | 10.45× | Reported |
| 2016-03-26 | (m) | $1.40B | $40.39M | $214.92M | $16.26M | (m) | 2.89% | 13.22× | Reported |
| 2015-12-26 | (m) | $1.36B | $40.12M | $206.45M | $15.07M | (m) | 2.94% | 13.70× | Reported |
| 2015-09-26 | (m) | $1.34B | $38.25M | $194.95M | $14.03M | (m) | 2.86% | 13.90× | Reported |
| 2015-06-27 | (m) | $1.32B | $36.03M | $185.68M | $13.18M | (m) | 2.74% | 14.09× | Reported |
| 2015-03-28 | (m) | $1.32B | $34.05M | $180.97M | $12.17M | (m) | 2.58% | 14.87× | Reported |
| 2014-12-27 | (m) | $1.30B | $31.04M | $177.67M | $11.95M | (m) | 2.39% | 14.87× | Reported |
| 2014-09-27 | (m) | $1.26B | $29.44M | $161.51M | $12.00M | (m) | 2.34% | 13.46× | Reported |
| 2014-06-28 | (m) | $1.22B | $27.24M | $156.18M | $11.32M | (m) | 2.23% | 13.80× | Reported |
| 2014-03-29 | (m) | $1.17B | $25.30M | $148.34M | $15.49M | (m) | 2.16% | 9.58× | Reported |
| 2013-12-28 | (m) | $1.17B | $24.54M | $151.40M | $20.97M | (m) | 2.11% | 7.22× | Reported |
| 2013-09-28 | (m) | $1.16B | $24.26M | $161.86M | $26.45M | (m) | 2.10% | 6.12× | Reported |
| 2013-06-29 | (m) | $1.14B | $23.45M | $158.70M | $32.65M | (m) | 2.05% | 4.86× | Reported |
| 2013-03-30 | (m) | $1.13B | $22.49M | $164.79M | $33.19M | (m) | 1.98% | 4.97× | Reported |
| 2012-12-29 | (m) | $1.13B | $21.86M | $165.76M | $33.34M | (m) | 1.93% | 4.97× | Reported |
| 2012-09-29 | (m) | $1.14B | $20.61M | $172.34M | $35.00M | (m) | 1.81% | 4.92× | Reported |
| 2012-06-30 | (m) | $1.14B | $20.94M | $171.75M | $38.42M | (m) | 1.84% | 4.47× | Reported |
| 2012-03-31 | (m) | $1.14B | $21.05M | $175.79M | $41.01M | (m) | 1.84% | 4.29× | Reported |
| 2011-12-31 | (m) | $1.14B | $21.71M | $174.31M | $42.59M | (m) | 1.90% | 4.09× | Reported |
| 2011-09-24 | (m) | $1.13B | $21.16M | $-232.50M | $42.15M | (m) | 1.87% | -5.52× | Reported |
| 2011-06-25 | (m) | $1.13B | $22.26M | $-263.13M | $42.84M | (m) | 1.98% | -6.14× | Reported |
| 2011-03-26 | (m) | $1.13B | $24.59M | $-286.45M | $39.29M | (m) | 2.18% | -7.29× | Reported |
| 2010-12-25 | (m) | $1.13B | $25.53M | $-298.51M | $35.28M | (m) | 2.25% | -8.46× | Reported |
| 2010-09-25 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-26 | (m) | $1.17B | $23.65M | $169.61M | $21.68M | (m) | 2.02% | 7.82× | Reported |
| 2009-09-26 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-27 | (m) | $1.30B | $24.21M | $-451.84M | $22.34M | (m) | 1.87% | -20.23× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |